Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
|
31660987 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutation is associatedwith short PFS and the brain is the most common site of distant metastasis in patients with stage III non- squamous cell lung cancer treated with CCRT.
|
29914238 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR rs2233947 correlated with lung cancer in males, smokers, and in the squamous cell carcinoma lung cancer subtype (P<0.01).
|
31518089 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To analyze the distribution of epidermal growth factor receptor (<i>EGFR</i>) mutations; characterize the clinical and imageological features of lung squamous cell carcinoma (LSCC) in a large population of patients; and assess correlations between clinical and imageological characteristics and clinical outcomes of LSCC patients harboring <i>EGFR</i> mutations.
|
31695493 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An <i>EGFR</i> Sensitizing Mutation.
|
31802898 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
More macrophages were found in lung squamous cell carcinoma (LUSC) patients, patients with wild-type EGFR, and smokers than in patients with lung adenocarcinoma (LUAD), patients with EGFR mutations, and non-smokers.
|
31308749 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found EGFR-mutant LUAD showed significantly higher ITHi than KRAS-mutant LUAD/wild-type LUAD (P = 0.03) and numerically higher ITH than LUSC.
|
30626401 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Survival analysis found that TP53 and EGFR showed a significant correlation (log rank P = 3e-07 and 0.023) with lung adenocarcinoma and lung squamous cell carcinoma, according to KM analysis.
|
31544704 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
|
31283542 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fourteen epidermal growth factor receptor (EGFR)-mutant LSCC patients treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy were enrolled for validation dataset.
|
30643941 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Concurrent inhibition of the PD-1 and epidermal growth factor receptor (EGFR) pathways represents a rational approach to improve responses and delay the onset of treatment resistance in lung SCC.
|
30808583 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach.
|
30788361 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 10.5% of the LUSC subgroup had somatic alterations with therapeutic relevance, including in EGFR (2.8%), ALK/ROS1 (1.3%), BRAF (1.5%), and MET amplification or exon 14 skipping (5.1%).
|
30279110 |
2019 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.
|
29143497 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Significant differences in NIC, K values, and calcium content were observed between the EGFR-positive and EGFR-negative groups among patients with SC.
|
29752156 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the feasibility of applying this method to mediastinal lymph node metastases in an epidermal growth factor receptor (EGFR)-positive squamous cell carcinoma of the lung.
|
29856819 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The administration of afatinib to Sq patients after selecting patients using the EGFR mutation test based on their underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib.
|
29446042 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although the majority of these advances took place in the non-squamous histological subtype, therapeutic options for patients diagnosed with advanced squamous cell lung cancer (SqCLC) have been also enriched significantly with the addition of nab-paclitaxel in the conventional chemotherapy; the introduction of necitumumab, afatinib and erlotinib in the inhibition of epidermal growth factor receptor (EGFR) axis and of ramucirumab in the inhibition of VEGF-induced angiogenesis and last with the approvals of nivolumab, pembrolizumab atezolizumab and durvalumab soon in the promising field of immunotherapies.
|
29862232 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGFR copy number gain by FISH might have a role as a predictive biomarker for necitumumab in squamous cell lung cancer.
|
29158193 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therapy with EGFR-directed mAbs in combination with chemotherapy is associated with greater clinical benefits in patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein and/or have increased EGFR gene copy number.
|
29905778 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
After propensity score matching, 78 EGFR-mutated lung SCC and 78 EGFR-mutated lung ADC patients were selected and compared.
|
30109777 |
2018 |
Squamous cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer.
|
27835914 |
2017 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The EGFR-TKIs had a modest response for EGFR mutated lung squamous cell carcinoma patients and might be a selective option for those patients.
|
28881841 |
2017 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery.
|
28272214 |
2017 |
Squamous cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, the application of TKIs for lung squamous cell carcinoma (SCC), the second largest pathological subtype of NSCLC, remains controversial because available data for the EGFR mutation profile and frequency in SCC patients are limited.
|
29075127 |
2017 |